TDMS Study 05109-11 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
TRIETHANOLAMINE
NTP Experiment-Test: 05109-11 Report: PEIRPT05
Study Type: CHRONIC Date: 05/19/95
Route: DERMAL,SOLUTION Time: 23:24:43
Facility: Battelle Columbus Laboratory
Chemical CAS #: 102-71-6
Lock Date: 07/29/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05109-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 23:24:43
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 63 MG/KG 125 250
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Natural Death 14 17 13 15
Moribund Sacrifice 11 4 12 17
Survivors
Natural Death 1
Terminal Sacrifice 25 29 25 17
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (60) (60) (60) (60)
Periesophageal Tissue, Lipoma 1 (2%)
Liver (60) (60) (60) (60)
Hepatocellular Adenoma 1 (2%)
Mesentery (3) (2) (2) (2)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (50%)
Pancreas (60) (60) (60) (60)
Stomach, Forestomach (60) (60) (60) (60)
Squamous Cell Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60)
Schwannoma Benign 1 (2%)
Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60) (60) (60)
Adenoma 1 (2%) 1 (2%)
Adrenal Medulla (60) (60) (60) (59)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (60) (60) (60) (60)
Adenoma 2 (3%) 2 (3%)
Carcinoma 1 (2%)
Parathyroid Gland (51) (57) (57) (51)
Adenoma 1 (2%)
Page 2
NTP Experiment-Test: 05109-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 23:24:43
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 63 MG/KG 125 250
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Pituitary Gland (60) (60) (60) (60)
Pars Distalis, Adenoma 32 (53%) 26 (43%) 31 (52%) 27 (45%)
Pars Distalis, Adenoma, Multiple 1 (2%) 1 (2%) 1 (2%)
Thyroid Gland (60) (60) (60) (59)
C-Cell, Adenoma 1 (2%) 2 (3%) 2 (3%) 5 (8%)
C-Cell, Carcinoma 1 (2%)
Follicular Cell, Adenoma 2 (3%) 1 (2%) 2 (3%) 2 (3%)
Follicular Cell, Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (58) (59) (60) (60)
Adenoma 2 (3%) 6 (10%) 2 (3%) 2 (3%)
Carcinoma 1 (2%)
Bilateral, Carcinoma 1 (2%)
Ovary (60) (60) (60) (60)
Granulosa Cell Tumor Malignant 1 (2%)
Uterus (60) (60) (60) (60)
Leiomyoma 1 (2%)
Polyp Stromal 4 (7%) 2 (3%) 8 (13%) 7 (12%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60)
Lymph Node (6) (5) (6) (3)
Mediastinal, Rhabdomyosarcoma, Metastatic,
Skeletal Muscle 1 (33%)
Mediastinal, Schwannoma Malignant,
Metastatic, Heart 1 (20%)
Lymph Node, Mandibular (59) (60) (60) (60)
Lymph Node, Mesenteric (60) (60) (59) (60)
Spleen (60) (60) (60) (60)
Thymus (59) (57) (57) (58)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Thymoma Benign 1 (2%)
Thymoma Malignant 1 (2%)
Mediastinum, Schwannoma Malignant,
Metastatic, Heart 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05109-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 23:24:43
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 63 MG/KG 125 250
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (60) (60) (60) (60)
Adenoma 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Fibroadenoma 12 (20%) 13 (22%) 7 (12%) 6 (10%)
Fibroadenoma, Multiple 1 (2%) 3 (5%) 2 (3%)
Skin (60) (60) (60) (60)
Face, Squamous Cell Papilloma 1 (2%)
Inguinal, Keratoacanthoma 1 (2%)
Subcutaneous Tissue, Neurofibrosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (2)
Hemangiosarcoma 1 (100%)
Rhabdomyosarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60) (60) (60)
Medulloblastoma NOS 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Mediastinum, Rhabdomyosarcoma, Metastatic,
Skeletal Muscle 1 (2%)
Nose (60) (60) (60) (60)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (2) (1)
Middle Ear, Carcinoma, Metastatic, Zymbal's
Gland 1 (100%)
Pinna, Fibrosarcoma 1 (50%)
Zymbal's Gland (1) (1) (1)
Carcinoma 1 (100%) 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05109-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 23:24:43
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 63 MG/KG 125 250
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60)
Renal Tubule, Adenoma 1 (2%) 1 (2%)
Urinary Bladder (59) (60) (60) (60)
Leiomyoma 1 (2%)
Transitional Epithelium, Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Leukemia Mononuclear 13 (22%) 14 (23%) 13 (22%) 16 (27%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05109-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 23:24:43
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 63 MG/KG 125 250
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 50 44 47 44
Total Primary Neoplasms 79 79 77 76
Total Animals with Benign Neoplasms 45 39 42 37
Total Benign Neoplasms 59 61 62 55
Total Animals with Malignant Neoplasms 17 17 13 18
Total Malignant Neoplasms 20 18 15 20
Total Animals with Metastatic Neoplasms 1 2
Total Metastatic Neoplasm 2 5
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05109-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 23:24:43
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 32 MG/KG 63 MG/KG 125
MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 59 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Natural Death 9 12 6 8
Moribund Sacrifice 18 27 25 23
Accidently Killed 2
Survivors
Terminal Sacrifice 21 11 18 19
Animals Examined Microscopically 60 60 59 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (60) (60) (59) (60)
Leiomyosarcoma 1 (2%)
Intestine Small, Duodenum (60) (60) (59) (60)
Leiomyosarcoma, Metastatic, Intestine Large,
Colon 1 (2%)
Leiomyosarcoma, Metastatic, Stomach,
Glandular 1 (2%)
Intestine Small, Jejunum (60) (60) (59) (60)
Fibrous Histiocytoma, Metastatic, Spleen 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Intestine Small, Ileum (60) (60) (59) (60)
Fibrous Histiocytoma, Metastatic, Spleen 1 (2%)
Liver (60) (60) (59) (60)
Hepatocellular Carcinoma 1 (2%)
Hepatocellular Adenoma 3 (5%) 1 (2%)
Leiomyosarcoma, Metastatic, Intestine Large,
Colon 1 (2%)
Leiomyosarcoma, Metastatic, Stomach,
Glandular 1 (2%)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Mesentery (9) (10) (11) (5)
Leiomyosarcoma, Metastatic, Intestine Large,
Colon 1 (10%)
Leiomyosarcoma, Metastatic, Stomach,
Glandular 1 (9%)
Pancreas (60) (60) (59) (60)
Leiomyosarcoma, Metastatic, Intestine Large,
Colon 1 (2%)
Leiomyosarcoma, Metastatic, Stomach,
Glandular 1 (2%)
Page 7
NTP Experiment-Test: 05109-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 23:24:43
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 32 MG/KG 63 MG/KG 125
MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Salivary Glands (60) (60) (58) (60)
Neurofibrosarcoma, Metastatic, Skin 1 (2%)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Stomach, Forestomach (60) (60) (59) (60)
Squamous Cell Papilloma 1 (2%) 1 (2%) 1 (2%)
Stomach, Glandular (60) (60) (59) (60)
Leiomyosarcoma 1 (2%)
Leiomyosarcoma, Metastatic, Intestine Large,
Colon 1 (2%)
Tongue (1)
Squamous Cell Papilloma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (60) (60) (59) (59)
Heart (60) (60) (59) (60)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60) (59) (60)
Adrenal Medulla (60) (60) (59) (60)
Pheochromocytoma Complex 1 (2%)
Pheochromocytoma Benign 2 (3%) 8 (13%) 5 (8%) 3 (5%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (60) (60) (59) (60)
Adenoma 1 (2%) 3 (5%) 3 (5%) 5 (8%)
Parathyroid Gland (55) (57) (53) (56)
Adenoma 1 (2%)
Pituitary Gland (60) (60) (58) (60)
Pars Distalis, Adenoma 37 (62%) 40 (67%) 35 (60%) 39 (65%)
Pars Distalis, Adenoma, Multiple 1 (2%) 1 (2%) 2 (3%) 4 (7%)
Thyroid Gland (60) (60) (59) (60)
Neurofibrosarcoma, Metastatic, Skin 1 (2%)
Bilateral, C-Cell, Adenoma 1 (2%)
C-Cell, Adenoma 6 (10%) 4 (7%) 8 (14%) 6 (10%)
C-Cell, Carcinoma 1 (2%) 1 (2%)
Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05109-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 23:24:43
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 32 MG/KG 63 MG/KG 125
MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (60) (60) (59) (60)
Preputial Gland (60) (60) (58) (60)
Adenoma 1 (2%) 1 (2%)
Carcinoma 1 (2%) 1 (2%)
Fibrosarcoma 1 (2%)
Prostate (60) (59) (59) (60)
Adenocarcinoma 1 (2%) 1 (2%)
Sarcoma 1 (2%)
Seminal Vesicle (60) (60) (59) (60)
Testes (60) (60) (59) (60)
Bilateral, Interstitial Cell, Adenoma 16 (27%) 14 (23%) 16 (27%) 9 (15%)
Interstitial Cell, Adenoma 18 (30%) 26 (43%) 21 (36%) 20 (33%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (59) (60)
Lymph Node (15) (10) (16) (9)
Deep Cervical, Carcinoma, Metastatic,
Thyroid Gland 1 (6%)
Lymph Node, Mandibular (60) (60) (59) (60)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Lymph Node, Mesenteric (60) (60) (59) (59)
Spleen (60) (60) (59) (60)
Fibrous Histiocytoma 1 (2%)
Thymus (56) (59) (58) (59)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (58) (53) (54) (54)
Carcinoma 1 (2%) 1 (2%)
Fibroadenoma 1 (2%)
Skin (60) (60) (59) (60)
Basal Cell Adenoma 1 (2%)
Keratoacanthoma 1 (2%)
Abdominal, Ventral, Keratoacanthoma 1 (2%)
Dorsal, Keratoacanthoma 1 (2%)
Face, Basosquamous Tumor Malignant 1 (2%)
Face, Squamous Cell Papilloma 2 (3%) 1 (2%)
Head, Basosquamous Tumor Benign 1 (2%)
Hindlimb, Subcutaneous Tissue, Fibroma 1 (2%)
Inguinal, Keratoacanthoma 1 (2%)
Inguinal, Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Inguinal, Subcutaneous Tissue, Sarcoma 1 (2%)
Neck, Subcutaneous Tissue, Schwannoma
Page 9
NTP Experiment-Test: 05109-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 23:24:43
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 32 MG/KG 63 MG/KG 125
MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Malignant 1 (2%)
Pinna, Sarcoma 1 (2%)
Pinna, Squamous Cell Papilloma 1 (2%)
Site of Application-Mass, Basal Cell Adenoma 1 (2%)
Site of Application-Mass, Keratoacanthoma 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma,
Metastatic, Spleen 1 (2%)
Subcutaneous Tissue, Liposarcoma 1 (2%)
Subcutaneous Tissue, Neurofibrosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
Subcutaneous Tissue, Ventral, Fibroma 1 (2%)
Tail, Fibrosarcoma 1 (2%)
Thoracic, Keratoacanthoma 2 (3%) 1 (2%)
Thoracic, Subcutaneous Tissue, Fibroma 1 (2%) 1 (2%)
Ventral, Keratoacanthoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1) (1) (1)
Neurofibrosarcoma, Metastatic, Skin 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60) (58) (60)
Astrocytoma NOS 1 (2%)
Spinal Cord (2) (2)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (59) (60)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Nose (60) (60) (59) (60)
Squamous Cell Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (2) (2) (1)
Zymbal's Gland (2) (2) (1)
Carcinoma 2 (100%) 1 (50%) 1 (100%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05109-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 23:24:43
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 32 MG/KG 63 MG/KG 125
MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (59) (60)
Hemangiosarcoma 1 (2%)
Leiomyosarcoma, Metastatic, Intestine Large,
Colon 1 (2%)
Renal Tubule, Adenoma 1 (2%) 4 (7%) 2 (3%)
Urinary Bladder (60) (60) (58) (59)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(59) *(60)
Leukemia Mononuclear 25 (42%) 16 (27%) 21 (36%) 22 (37%)
Mesothelioma NOS 3 (5%) 2 (3%) 2 (3%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05109-11 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 23:24:43
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 32 MG/KG 63 MG/KG 125
MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 53 58 57 55
Total Primary Neoplasms 134 131 132 124
Total Animals with Benign Neoplasms 49 58 56 53
Total Benign Neoplasms 100 101 102 94
Total Animals with Malignant Neoplasms 27 23 27 26
Total Malignant Neoplasms 31 30 28 27
Total Animals with Metastatic Neoplasms 5 2 1
Total Metastatic Neoplasm 15 5 3
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 3 2 3
Total Uncertain Neoplasms 16 6 12
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------